

- 178 -

## Claims

1. Oxamide derivatives of formula I

5 A-D-B (I)

wherein

**D** is a bivalent oxamide moiety, or a derivative thereof,

A is a unsubstituted or substituted moiety of up to 40 carbon atoms of the formula:  $-L-(M-L')_{\alpha}$ , where L is a 5, 6 or 7 membered cyclic structure, preferably selected from the group consisting of aryl, heteroaryl, arylene and heteroarylene, bound directly to D, L' comprises an optionally substituted cyclic moiety having at least 5 members, preferably selected from the group consisting of aryl, heteroaryl, aralkyl, cycloalkyl and heterocyclyl, M is a bond or a bridging group having at least one atom,  $\alpha$  is an integer of from 1-4; and each cyclic structure of L and L' contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein L' is preferably substituted by at least one substituent selected from the group consisting of  $-\text{SO}_2\text{R}_x$ ,  $-\text{C}(\text{O})\text{R}_x$  and  $-\text{C}(\text{NR}_y)\text{R}_z$

**B** is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms, preferably of up to 20 carbon atoms, comprising at least one 5-, 6-, or 7-membered cyclic structure, preferably a 5- or 6-membered cyclic structure, bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein said cyclic structure directly bound to D is preferably selected from the group

- 179 -

consisting of aryl, heteroaryl and heterocyclyl,  $R_y$  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,

5

$R_z$  is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

10

$R_x$  is  $R_z$  or  $NR_aR_b$ , where  $R_a$  and  $R_b$  are

15

a) independently hydrogen, a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

20

-OSi( $R_f$ )<sub>3</sub> where  $R_f$  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

25

30

or

- 180 -

b)  $R_a$  and  $R_b$  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of  $R_a$  or  $R_b$  is  $-C(O)-$ , a  $C_1-C_5$  divalent alkylene group or a substituted  $C_1-C_5$  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted  $C_1-C_5$  divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

where B is substituted, L is substituted or L' is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and  $W_\gamma$ , where  $\gamma$  is 0-3;

wherein each W is independently selected from the group consisting of  $-CN$ ,  $-CO_2R$ ,  $-C(O)NR^5R^5$ ,  $-C(O)-R^5$ ,  $-NO_2$ ,  $-OR^5$ ,  $-SR^5$ ,  $-SO_2R^5$ ,  $-SO_3H$ ,  $-NR^5R^5$ ,  $-NR^5C(O)OR^5$ ,  $-NR^5C(O)R^5$ ,  $-Q-Ar$ , and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the groups consisting of  $-CN$ ,  $-CO_2R$ ,  $-C(O)NR^5R^5$ ,  $-C(O)-R^5$ ,  $-NO_2$ ,  $-OR^5$ ,  $-SR^5$ ,  $-SO_2R^5$ ,  $-SO_3H$ ,  $-NR^5R^5$ ,  $-NR^5C(O)OR^5$ , -

- 181 -

$\text{NR}^5\text{C}(\text{O})\text{R}^5$  and halogen up to per-halo; with each  $\text{R}^5$  independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is -O-, -S-, -N( $\text{R}^5$ )-, -( $\text{CH}_2$ ) $\beta$ -, -C(O)-, -CH(OH)-, -( $\text{CH}_2$ ) $\beta$ O-, -( $\text{CH}_2$ ) $\beta$ S-, -( $\text{CH}_2$ ) $\beta$ N( $\text{R}^5$ )-, -O( $\text{CH}_2$ ) $\beta$ -, -CHHal-, -CHal<sub>2</sub>-, -S-( $\text{CH}_2$ )- and -N( $\text{R}^5$ )( $\text{CH}_2$ ) $\beta$ - where  $\beta = 1-3$ , and Hal is halogen; and Ar is 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by  $\text{Z}_{\delta 1}$  wherein  $\delta 1$  is 0 to 3 and each Z is independently selected from the group consisting -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5</sup>, -C(O)-R<sup>5</sup>, -NO<sub>2</sub>, -OR<sup>5</sup>, -SR<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SO<sub>3</sub>H, -NR<sup>5</sup>R<sup>5</sup>, -NR<sup>5</sup>C(O)OR<sup>5</sup>, -NR<sup>5</sup>C(O)R<sup>5</sup>, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5</sup>, -C(O)-R<sup>5</sup>, -NO<sub>2</sub>, -OR<sup>5</sup>, -SR<sup>5</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SO<sub>3</sub>H, -NR<sup>5</sup>R<sup>5</sup>, -NR<sup>5</sup>C(O)OR<sup>5</sup>, -NR<sup>5</sup>C(O)R<sup>5</sup>, and the pharmaceutically acceptable derivatives, salts and solvates thereof.

2. Oxamide derivative according to claim 1, characterised in that each M independently from one another represents a bond or is a bridging group, selected from the group consisting of ( $\text{CR}^5\text{R}^5$ )<sub>n</sub>, or ( $\text{CHR}^5$ )<sub>n</sub>-Q-( $\text{CHR}^5$ )<sub>i</sub>, wherein

Q is selected from a group consisting of O, S, N-R<sup>5</sup>, (CHal<sub>2</sub>)<sub>j</sub>, (O-CHR<sup>5</sup>)<sub>i</sub>, (CHR<sup>5</sup>-O)<sub>i</sub>, CR<sup>5</sup>=CR<sup>5</sup>, (O-CHR<sup>5</sup>CHR<sup>5</sup>)<sub>i</sub>,

- 182 -


$(\text{CHR}^5\text{CHR}^5\text{-O})_j$ ,  $\text{C=O}$ ,  $\text{C=S}$ ,  $\text{C=NR}^5$ ,  $\text{CH(OR}^5\text{)}$ ,  $\text{C(OR}^5\text{)(OR}^5\text{)}$ ,  
 $\text{C(=O)O}$ ,  $\text{OC(=O)}$ ,  $\text{OC(=O)O}$ ,  $\text{(C=O)N(R}^5\text{)C(=O)}$ ,  $\text{OC(=O)N(R}^5\text{)}$ ,  
 $\text{N(R}^5\text{)C(=O)O}$ ,  $\text{CH=N-NR}^5$ ,  $\text{S=O}$ ,  $\text{SO}_2$ ,  $\text{SO}_2\text{NR}^5$  und  $\text{NR}^5\text{SO}_2$ ,  
 wherein

$\text{R}^5$  is in each case independently selected from the meanings given  
 above, preferably hydrogen, halogen, alkyl, aryl, aralkyl,

$h, i$  are independently from each other 0, 1, 2, 3, 4, 5, or 6,  
 preferably 0, 1, 2 or 3, and

$j$  is 1, 2, 3, 4, 5 or 6, preferably 0, 1, 2 or 3.

3. Oxamide derivative according to claim 1 or 2, selected from the  
 compounds of formula II,



wherein

$\text{Ar}^1, \text{Ar}^2$  are selected independently from one another from  
 aromatic hydrocarbons containing 6 to 14 carbon atoms  
 and ethylenical unsaturated or aromatic heterocyclic  
 residues containing 3 to 10 carbon atoms and one or two  
 hetero atoms, independently selected from N, O und S,

$\text{R}^8, \text{R}^9$  and  $\text{R}^{10}$  are independently selected from a group consisting of  
 H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal,  
 $\text{CH}_2\text{Hal}$ ,  $\text{CH(Hal)}_2$ ,  $\text{C(Hal)}_3$ ,  $\text{NO}_2$ ,  $(\text{CH}_2)_n\text{CN}$ ,

- 183 -

$(CH_2)_nNR^{11}R^{12}$ ,  $(CH_2)_nOR^{11}$ ,  $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$ ,  
 $(CH_2)_nCOOR^{12}$ ,  $(CH_2)_nCONR^{11}R^{12}$ ,  $(CH_2)_nNR^{11}COR^{13}$ ,  
 $(CH_2)_nNR^{11}CONR^{11}R^{12}$ ,  $(CH_2)_nNR^{11}SO_2A$ ,  
 $(CH_2)_nSO_2NR^{11}R^{12}$ ,  $(CH_2)_nS(O)_uR^{13}$ ,  $(CH_2)_nOC(O)R^{13}$ ,  
 $(CH_2)_nCOR^{13}$ ,  $(CH_2)_nSR^{11}$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  
 $(CH_2)_nNHOA$ ,  $(CH_2)_nCH=N-R^{11}$ ,  $(CH_2)_nOC(O)NR^{11}R^{12}$ ,  
 $(CH_2)_nNR^{11}COOR^{12}$ ,  $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$ ,  
 $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$ ,  
 $C(R^{13})HCOR^{12}$ ,  $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$ ,  
 $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$ ,  $CH=CHCOOR^{11}$ ,  
 $CH=CHCH_2NR^{11}R^{12}$ ,  $CH=CHCH_2NR^{11}R^{12}$ ,  
 $CH=CHCH_2OR^{13}$ ,  $(CH_2)_nN(COOR^{11})COOR^{12}$ ,  
 $(CH_2)_nN(CONH_2)COOR^{11}$ ,  $(CH_2)_nN(CONH_2)CONH_2$ ,  
 $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$ ,  
 $(CH_2)_nN(CH_2CONH_2)COOR^{11}$ ,  
 $(CH_2)_nN(CH_2CONH_2)CONH_2$ ,  $(CH_2)_nCHR^{13}COR^{11}$ ,  
 $(CH_2)_nCHR^{13}COOR^{11}$ ,  $(CH_2)_nCHR^{13}CH_2OR^{14}$ ,  $(CH_2)_nOCN$   
 and  $(CH_2)_nNCO$ , wherein

$R^{11}$ ,  $R^{12}$  are independently selected from a group consisting of H,  
 A,  $(CH_2)_mAr^3$  and  $(CH_2)_mHet$ , or in  $NR^{11}R^{12}$ ,

$R^{11}$  and  $R^{12}$  form, together with the N-Atom they are bound to, a 5-,  
 6- or 7-membered heterocyclus which optionally contains 1  
 or 2 additional hetero atoms, selected from N, O and S,

$R^{13}$ ,  $R^{14}$  are independently selected from a group consisting of H,  
 Hal, A,  $(CH_2)_mAr^4$  and  $(CH_2)_mHet$ ,

A is selected from the group consisting of alkyl, alkenyl,  
 cycloalkyl, alkylencycloalkyl, alkoxy and alkoxyalkyl,

- 184 -

- 5       $Ar^3, Ar^4$       are independently from one another aromatic hydrocarbon residues comprising 5 to 12 and preferably 5 to 10 carbon atoms which are optionally substituted by one or more substituents, selected from a group consisting of A, Hal,  $NO_2$ , CN,  $OR^{15}$ ,  $NR^{15}R^{16}$ ,  $COOR^{15}$ ,  $CONR^{15}R^{16}$ ,  $NR^{15}COR^{16}$ ,  $NR^{15}CONR^{15}R^{16}$ ,  $NR^{16}SO_2A$ ,  $COR^{15}$ ,  $SO_2R^{15}R^{16}$ ,  $S(O)_uA$  and  $OOCR^{15}$ ,
- 10      Het      is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from a group consisting of A, Hal,  $NO_2$ , CN,  $OR^{15}$ ,  $NR^{15}R^{16}$ ,  $COOR^{15}$ ,  $CONR^{15}R^{16}$ ,  $NR^{15}COR^{16}$ ,  $NR^{15}CONR^{15}R^{16}$ ,  $NR^{16}SO_2A$ ,  $COR^{15}$ ,  $SO_2R^{15}R^{16}$ ,  $S(O)_uA$  and  $OOCR^{15}$ ,
- 15       $R^{15}, R^{16}$       are independently selected from a group consisting of H, A, and  $(CH_2)_mAr^5$ , wherein
- 20       $Ar^5$       is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from a group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH,  $NH_2$  and  $CF_3$ ,
- 25      k, m and n      are independently of one another 0, 1, 2, 3, 4, or 5;
- 30      X      represents a bond or is  $(CR^{11}R^{12})_h$ , or  $(CHR^{11})_h-Q-(CHR^{12})_i$ , wherein
- 30      Q      is selected from a group consisting of O, S,  $N-R^{15}$ ,  $(CHal_2)_j$ ,  $(O-CHR^{18})_j$ ,  $(CHR^{18}-O)_j$ ,  $CR^{18}=CR^{19}$ ,  $(O-CHR^{18}CHR^{19})_j$ ,  $CHR^{18}CHR^{19}-O)_j$ , C=O, C=S,  $C=NR^{15}$ ,  $CH(OR^{15})$ ,

- 185 -

$C(OR^{15})(OR^{20})$ ,  $C(=O)O$ ,  $OC(=O)$ ,  $OC(=O)O$ ,  $C(=)N(R^{15})$ ,  
 $N(R^{15})C(=O)$ ,  $CH=N-O$ ,  $CH=N-NR^{15}$ ,  $OC(O)NR^{15}$ ,  
 $NR^{15}C(O)O$ ,  $S=O$ ,  $SO_2$ ,  $SO_2NR^{15}$  und  $NR^{15}SO_2$ , wherein

5  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  are independently selected from the meanings given for  
 $R^8$ ,  $R^9$  and  $R^{10}$ ,

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, and

10 j is 1, 2, 3, 4, 5 or 6,

Y is selected from O, S,  $NR^{21}$ ,  $C(R^{22})-NO_2$ ,  $C(R^{22})-CN$  and  
 $C(CN)_2$ , wherein

15  $R^{21}$  is independently selected from the meanings given for  $R^{13}$ ,  
 $R^{14}$ , and

$R^{22}$  is independently selected from the meanings given for  $R^{11}$ ,  
 $R^{12}$ ,

20 p, r are independently from one another 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4, preferably 0, 1 or 2,

25 u is 0, 1, 2 or 3, preferably 0, 1 or 2,

and

30 Hal is independently selected from a group consisting of F, Cl,  
Br and I;




- 186 -

and the pharmaceutically acceptable derivatives, salts and solvates thereof.


4. Oxamide derivative according to one of the claims 1 to 3, selected from the compounds of formula IIa, IIb, IIc, IId, IIe, IIg and IIh,

10




IIa

15




IIb

20



IIc


25




IId

30


- 187 -




IIe



IIlf



IIlg



IIlh

wherein  $R^6$ ,  $R^7$ ,  $R^8$ ,  $p$ ,  $X$ ,  $Y$ ,  $R^9$ ,  $q$  are as defined in claim 3 and  $R^{10}$  is H or as defined in claim 3;

and the pharmaceutically acceptable derivatives, salts and solvates thereof.

5. Oxamide derivative according to claim one of the claims 1, 2 or 3, selected from the compounds (1) to (224) of table 1, and the pharmaceutically acceptable derivatives, salts and solvates thereof.

- 188 -

6. Oxamide derivative according to one of the claims 1 to 5 as a medicament.
- 5 7. Oxamide derivative according to one of the claims 1 to 5 as a kinase inhibitor.
8. Oxamide derivative according to claim 7, characterized in that the kinases are selected from raf-kinases.
- 10 9. Pharmaceutical composition, characterized in that it contains one or more compounds according to one of the claims 1 to 5.
- 15 10. Pharmaceutical composition according to claim 9, characterised in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients other than the compounds according to one of the claims 1 to 5.
- 20 11. Process for the manufacture of a pharmaceutical composition, characterised in that one or more compounds according to one of the claims 1 to 5 and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to one of the claims 1 to 5, is processed by mechanical means into a  
25 pharmaceutical composition that is suitable as dosageform for application and/or administration to a patient.
- 30 12. Use of a compound according to one of the claims 1 to 5 as a pharmaceutical.
13. Use of a compound according to one of the claims 1 to 5 in the treatment and/or prophylaxis of disorders.

- 189 -

- 5
14. Use of a compound according to one of the claims 1 to 5 for producing a pharmaceutical composition for the treatment and/or prophylaxis of disorders.
15. Use according to claim 13 or 14, characterised in that the disorders are caused, mediated and/or propagated by raf-kinases.
- 10
16. Use according to claim 13, 14 or 15, characterised in that the disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.
- 15
17. Use according to claim 13, 14, 15 or 16, characterised in that the disorder is cancer.
18. Use according to claim 13, 14, 15 or 16, characterised in that the disorder is noncancerous.
- 20
19. Use according to claim 13, 14, 15, 16 or 18, characterised in that the noncancerous disorders are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, Helicobacter pylori infection, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.
- 25
20. Use according to one of the claims 13 to 17, characterised in that the disorders are selected from the group consisting of melanoma, brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancer, ovary cancer, uterine cancer, prostate cancer, thyroid cancer, lymphoma, chronic
- 30

- 190 -

leukaemia and acute leukaemia.

- 5           21. Use according to one of the claims 15 to 19, characterised in that the disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation, solid tumors, rheumatic arthritis, diabetic retinopathy, and neurodegenerative
- 10           diseases.
- 15           22. Use according to one of the claims 15 to 18, characterised in that the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.
- 20           23. Use of a compound according to one of the claims 1 to 5 as a raf-kinase inhibitor.
- 25           24. Use according to claim 23, characterised in that the raf-kinase is selected from the group consisting of A-Raf, B-Raf and c-Raf-1.
- 30           25. Method for the treatment and/or prophylaxis of disorders, characterised in that one or more compounds according to one of the claims 1 to 5 is administered to a patient in need of such a treatment.
26. Method according to claim 25, characterised in that the one or more compounds according to one of the claims claim 1 to 5 are administered as a pharmaceutical composition according to claim 9 or 10.


- 191 -

27. Method for the treatment and/or prophylaxis of disorders according to claim 26, characterised in that the disorders are as defined in one of the claims 15 to 22.

28. Method for the treatment according to claim 27, characterised in that the disorders is cancerous cell growth mediated by raf-kinase.

29. Method for producing compounds of formula II, characterised in that

a) a compound of formula III




wherein

$L^1$  is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and  $R^8$ ,  $p$ ,  $Ar^1$ ,  $Y$  are as defined in claim 3,

is reacted

b) with a compound of formula IV,



wherein


- 192 -

$L^2, L^3$  are independently from one another H or a metal ion, and  $R^9$ ,  $q$ ,  $X$ ,  $Ar^2$ ,  $R^{10}$  and  $r$  are as defined in claim 3,

5 and optionally

c) isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

10 30. Compound of formula III,




15

wherein

$L^1$  is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and  $R^8$ ,  $p$ ,  $Ar^1$ ,  $Y$  are as defined in claim 3.

20

31. Compound of formula IV,



25

wherein

$L^2, L^3$  are independently from one another H or a metal ion, and  $R^9$ ,  $q$ ,  $X$ ,  $Ar^2$ ,  $R^{10}$  and  $r$  are as defined in claim 3.

30